LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

Authors :: David Magrez
PD Dr. Schattenberg Jörn
Rémy Hanf
John M. Vierling
S. Megnien
Stephen H. Caldwell
David Jones
MB Bchir
Cynthia Levy
Kris V. Kowdley
Velimir A. Luketic
Daniel Pratt
Pascal Birman
Albert Parés
Alan Bonder
Gideon M. Hirschfield
Michael A. Heneghan
Source :: Journal of Hepatology. 70:e128
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Agonist
Hepatology
Peroxisome proliferator
medicine.drug_class
business.industry
Alpha (ethology)
Elafibranor
Pharmacology
Ursodeoxycholic acid
medicine
In patient
business
Receptor
medicine.drug

Full Text Access

Tools